个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Wei Xiaoting[1] ; Zou Zhengyun[2] ; Zhang Weizhen[3] ; Fang Meiyu[4] ; Zhang Xiaoshi[5] ; Luo Zhiguo[6] ; Chen Jing[7] ; Huang Gang[8] ; Zhang Peng[9] ; Cheng Ying[10] ; Liu Jiwei[11] ; Liu Jiyan[12] ; Zhang Junping[13] ; Wu Di[14] ; Chen Yu[15] ; Ma Xiaobiao[16] ; Pan Hongming[17] ; Jiang Renbing[18] ; Liu Xinlan[19] ; Ren Xiubao[20] ; Tian Hongqi[22] ; Jia Zhongwei[21] ; Guo Jun[1] ; Si Lu[1,*1] ;
机构： [1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and [2]Comprehensive Cancer Center (word B7) of Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China [3]Department of Internal Medicine of Melanoma and Sarcoma, the Third People’s Hospital of Zhengzhou, Henan, China [4]Department of Rare Cancer & Head and Neck Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, [5]State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China [6]Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China [7]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Cancer Centre, Wuhan, China [8]Department of Orthopedics & Soft Tissue, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan, [9]Department of Bone and Soft Tissue Cancer, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China [10]Department of Medical Oncology, Jilin Cancer Hospital, Changchun, China [11]Department of Medical Oncology/the First Affiliated Hospital of Dalian Medical University, Dalian, China [12]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China [13]Department of Thoracic Oncology, Shanxi Bethune Hospital, Taiyuan, China [14]Department of Cancer Center, First Hospital of Jilin University, Changchun, China [15]Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China [16]Department of Cancer Biotherapy Center, Yunnan Cancer Hospital, the Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, [17]Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Medical Oncology, Zhejiang, China [18]Department of Bone and Soft Tissue, the Affiliated Tumor Hospital of Xinjiang Medical University, Xinjiang, China [19]Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, China [20]Tianjin Medical University Cancer Institute & Hospital, Biotherapy Department, Tianjin, China [21]Department of Clinical Research and Development, Shanghai Kechow Pharma, Inc., Shanghai, China [22]Shanghai Kechow Pharma, Inc., Shanghai, China
出处：
DOI： 10.1016/j.ejca.2024.114008
ISSN：

关键词： Melanoma NRAS mutation MEK inhibitor tunlametinib

摘要：
NRAS-mutant melanoma is an aggressive subtype with poor prognosis; however, there is no approved targeted therapy to date worldwide.We conducted a multicenter, single-arm, phase II, pivotal registrational study that evaluated the efficacy and safety of the MEK inhibitor tunlametinib in patients with unresectable, stage III/IV, NRAS-mutant melanoma (NCT05217303). The primary endpoint was objective response rate (ORR) assessed by independent radiological review committee (IRRC) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The secondary endpoints included progression-free survival (PFS), disease control rate (DCR), duration of response(DOR), overall survival (OS) and safety.Between November 2, 2020 and February 11, 2022, a total of 100 patients were enrolled. All (n = 100) patients received at least one dose of tunlametinib (safety analysis set [SAS]) and 95 had central laboratory-confirmed NRAS mutations (full analysis set [FAS]). In the FAS, NRAS mutations were observed at Q61 (78.9%), G12 (15.8%) and G13 (5.3%). The IRRC-assessed ORR was 35.8%, with a median DOR of 6.1 months. The median PFS was 4.2 months, DCR was 72.6% and median OS was 13.7 months. Subgroup analysis showed that in patients who had previously received immunotherapy, the ORR was 40.6%. No treatment-related deaths occurred.Tunlametinib showed promising antitumor activity with a manageable safety profile in patients with advanced NRAS-mutant melanoma, including those who had prior exposure to immunotherapy. The findings warrant further validation in a randomized clinical trial.Copyright © 2024. Published by Elsevier Ltd.

基金：
This study was sponsored by Shanghai Kechow Pharma, Inc.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and
共同第一作者：
通讯作者：
通讯机构： [1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and [*1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing 100142, China
推荐引用方式(GB/T 7714)：
Wei Xiaoting,Zou Zhengyun,Zhang Weizhen,et al.A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma[J].European Journal Of Cancer (Oxford, England : 1990).2024,202:114008.doi:10.1016/j.ejca.2024.114008.
APA：
Wei Xiaoting,Zou Zhengyun,Zhang Weizhen,Fang Meiyu,Zhang Xiaoshi...&Si Lu.(2024).A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.European Journal Of Cancer (Oxford, England : 1990),202,
MLA：
Wei Xiaoting,et al."A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma".European Journal Of Cancer (Oxford, England : 1990) 202.(2024):114008

相关文献

[1]A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma [2]Investigation of indoleamine 2,3-dioxygenase 1 expression in uveal melanoma. [3]足底部恶性黑色素瘤切除术后两种修复方法临床疗效观察 [4]The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series [5]神经皮肤黑变病并颅内恶性黑色素瘤一例 [6]YAP activation in melanoma contributes to anoikis resistance and metastasis. [7]Nanomedicine in the application of uveal melanoma. [8]A highly potent and selective inhibitor Roxyl-WL targeting IDO1 promotes immune response against melanoma. [9]Applying an innovative biodegradable self-assembly nanomicelles to deliver α-mangostin for improving anti-melanoma activity. [10]A Rare Presentation of Melanoma as a Retroperitoneal Mass Seen on FDG PET

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号